Ablynx NV, of Ghent, Belgium, appointed Edwin Moses nonexecutive chairman.
Aeolus Pharmaceuticals Inc., of Research Triangle Park, N.C., appointed Brian Day chief scientific officer.
Affymetrix Inc., of Santa Clara, Calif., appointed Susan Desmond-Hellmann to its board.
Alba Therapeutics Corp., of Baltimore, appointed Allen Sedman to its scientific advisory board.
Albany Molecular Research Inc., of Albany, N.Y., appointed Mark Frost chief financial officer.
American Pharmaceutical Partners Inc., of Schaumburg, Ill., appointed Alan Heller president and CEO.
Amphora Discovery Corp., of Research Triangle Park, N.C., named Paul Steed executive director, preclinical biology, and Carla Suto executive director, high-throughput biology.
BioAdvance, of Philadelphia, appointed Michael Pellini an entrepreneur-in-residence.
Biogen Idec Inc., of Cambridge, Mass., said James Mullen and other members of the senior management team will assume responsibilities of retiring Chief Operating Officer William Rohn.
BIOQuebec, of Montreal, elected Bertrand Bolduc president.
Cytomedix Inc., of Rockville, Md., appointed Arun Deva to its board.
Discovery Laboratories Inc., of Doylestown, Pa., appointed Stephen Gavel vice president of sales, and Thomas Miller vice president of marketing.
Diversa Corp., of San Diego, appointed Anthony Altig senior vice president of finance and chief financial officer.
Dow Pharmaceutical Sciences, of Petaluma, Calif., appointed Sandra Calman director of clinical research.
Encysive Pharmaceuticals Inc., of Houston, appointed John Dillon to its board.
Forbes Medi-Tech Inc., of Vancouver, British Columbia, appointed Steven Nissen chairman of its medical and scientific advisory board.
GenVec Inc., of Gaithersburg, Md., appointed Nita Patel vice president of regulatory affairs.
Guilford Pharmaceuticals Inc., of Baltimore, appointed Dean Mitchell president and CEO.
ImmuneRegen BioSciences, of Scottsdale, Ariz., appointed William Hoehn to its bioterrorism preparedness advisory board.
InNexus Biotechnology Inc., of Vancouver, British Columbia, named Jeff Morhet vice president of operations.
LION bioscience AG, of Heidelberg, Germany, reappointed its executive board, naming Thure Etzold CEO and Peter Willinger chief financial officer. Joseph Donahue remains responsible for global sales and continues as president of LION bioscience Inc.
Migenix Inc., of Vancouver, British Columbia, appointed Keith Schilit to its board.
Nabi Biopharmaceuticals, of Boca Raton, Fla., appointed Pamela Barton vice president, business development.
Neurobiological Technologies Inc., of Richmond, Calif., appointed Ronald Cape to its board, and named Jonathan Wolter vice president and chief financial officer.
Orchid BioSciences Inc., of Princeton, N.J., appointed Warren Meltzer vice president of legal affairs and general counsel.
PhotoCure ASA, of Oslo, Norway, appointed Grete Hogstad vice president marketing and sales, Pal Brathen vice president business development, and Christian Fekete chief financial officer.
Predicant Biosciences, of South San Francisco, appointed Richard Bastiani to its board.
Prestwick Pharmaceuticals Inc., of Washington, appointed William Washecka chief financial officer.
Reliant Technologies Inc., of San Diego, appointed Glen Nelson to its board.
Response Biomedical Corp., of Vancouver, British Columbia, appointed Sidney Braginsky to its board, and Robert Pilz chief financial officer and vice president of finance.
Southern Research Institute in Birmingham, Ala., appointed Colleen Jonsson director of the emerging pathogens research department.
Spectranetics Corp., of Colorado Springs, Colo., appointed Mel Backlin director of sales.
Tm Bioscience Corp., of Toronto, appointed Paul Lucas chairman of its board, Neil Reid vice chairman, and Michael Mueller director.
Viropro Pharma, of Montreal, nominated Jean-Louis Boitieux to its scientific advisory board.
Vivus Inc., of Mountain View, Calif., appointed Timothy Morris vice president of finance and chief financial officer.